Download full announcement 

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence (“AI”) enabled clinical diagnostics solutions for kidney disease, notes the announcement today by EKF Diagnostics Holdings plc (AIM: EKF) and confirms that it has agreed a different resolution to the requirement for one of the two companies to appoint a new nominated adviser.

The proposed change remains driven by the regulatory requirement for an AIM issuer to retain an independent nominated adviser. Following EKF Diagnostics Holdings plc’s (“EKF”) decision to invest in the placing which took place alongside the admission to trading on AIM of Renalytix AI plc (“RenalytixAI”), it was no longer possible for N+1 Singer to continue to act as an independent nominated adviser to both companies.

By mutual agreement of all parties, N+1 Singer will now remain nominated adviser and broker to EKF. To preserve the independence of its nominated adviser, RenalytixAI will appoint a new nominated adviser and joint broker, with US distribution capability which aligns with the Company’s US-based business operations and the initial target market for its products.

N+1 Singer will continue to act as nominated adviser and broker to RenalytixAI in the interim, and as joint broker following the appointment of a joint broker and new nominated adviser. A further announcement will be made in the New Year with regard to the new appointment.

Enquiries:

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.